Atezolizumab After Single or Multiple Fractions of Stereotactic Radiotherapy in TNBC

Advanced triple-negative breast cancer may benefit from an unexpected combination: stereotactic ablative body radiotherapy (SABR) delivered either in a single fraction or multiple fractions, followed by the immunotherapy atezolizumab. In a randomized phase II trial, investigators asked whether precisely targeted radiation could prime tumors for immune attack, improving outcomes beyond what either modality might achieve alone.

The study enrolled participants with advanced disease and compared two SABR schedules: a single-fraction approach versus a multi-fraction regimen. After radiation, all patients received atezolizumab, an anti–PD-L1 monoclonal antibody designed to release brakes on cytotoxic T cells. By pairing high-dose, image-guided tumor irradiation with PD-L1 blockade, the researchers aimed to enhance local control while also stimulating systemic responses.

Technically, SABR focuses ablative doses onto tumor deposits while minimizing exposure to surrounding organs through rigorous planning and delivery accuracy. This “precision radiotherapy” strategy is distinct from conventional fractionation, which spreads dose more broadly over time. The trial’s key question was not only whether SABR plus atezolizumab could work, but whether fractionation style would matter when an immunotherapy is given afterward.

Patients were monitored for clinical endpoints typical of phase II development, including response measures and progression-related outcomes. The investigators also evaluated safety, with particular attention to immunotherapy-associated adverse events and radiation-related toxicities. In this context, the balance between achieving tumor ablation and avoiding harm to nearby tissues is crucial.

Results indicate that SABR followed by atezolizumab is feasible in advanced triple-negative breast cancer across both fractionation strategies. The comparison between single- and multi-fraction delivery provides an early signal that the regimen can be tailored without sacrificing the immunotherapy partnership. Such flexibility could simplify decision-making in routine practice, where treatment timing and patient tolerance often drive regimen selection.

The trial also supports the broader concept that radiation can function as an “in situ vaccine.” By causing tumor antigen release and modulating the tumor microenvironment, SABR may increase susceptibility to immune checkpoint inhibition. If confirmed in larger studies, this paradigm could alter sequencing standards for patients with limited targeted options.

For a disease that frequently evades durable control, the randomized phase II design strengthens the relevance of the findings. The authors report their work in Nature Communications (2026), adding a new randomized framework for how stereotactic radiation and PD-L1 blockade might be integrated.